BioFactura

4 articles about BioFactura

• BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar

  5/25/2021

  First clinical trial from BioFactura’s pipeline of high-value biosimilar and biodefense drugs BFI-751: Biosimilar designed to treat people with Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis Study to assess safety and tolerability of 751-BFI and evaluate pharmacokinetics in comparison to Stelara®

• BioFactura Awarded $67.4 Million Advanced Development Contract for Its Smallpox Biodefense Therapeutic

  9/26/2019

  This product has the potential to fulfill an unmet need in preparedness for a second anti-viral therapeutic with a different mechanism of action to the current stockpile to guard against potential host resistance.

• MdBio Foundation Awards Final Milestone Payment to BioFactura

  9/12/2012

• BioFactura Awarded US Patent for its StableFastTM Biomanufacturing Platform

  11/22/2011